The Global Structural Heart Devices Market valued at $6.6 billion in 2021 is set to witness a growth rate of 10% in the next 5 years. The rising geriatric population & corresponding rise in the ...

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Boston Scientific said it still expects to achieve its second-quarter and full-year 2025 sales and adjusted per-share earnings guidance despite the anticipated financial impacts from the ...

According to the study’s abstract in The Lancet, TAVR with Acurate neo2 failed to meet non-inferiority. It also resulted in ...

New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms ...